Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor used in the management of type 2 diabetes mellitus. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria.
- Mechanism
- Curator reviewed · 3 references
Dapagliflozin inhibits the sodium-glucose cotransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron. SGLT2 facilitates 90% of glucose reabsorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine. This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.
- Primary indication
- Dapagliflozin is indicated as an adjunct treatment, alongside diet and exercise, to improve glycemic control in patients ≥10 years of age with type 2 diabetes mellitus.Curator reviewed · 11 structured indications
- Formula / weight
- C21H25ClO6 · 408.873 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2008 · European Union, 2016
- Code names
- BMS-512148
- Brand names
Resolves to
JVHXJTBJCFBINQ-ADAARDCZSA-NSMILESCCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Dapagliflozin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account